Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)

尼莫地平全身暴露和动脉瘤性蛛网膜下腔出血后的结果：一项前瞻性多中心观察研究（ASH-II 研究）

• 批准号: 494000
• 负责人: Mahmoud Sherif H
• 金额: $ 7.29万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-09-01 至 2024-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=494000&lang=en
• 关键词: Chiral Compound; Nimodipine; Pharmacokinetics; Subarachnoid Hemorrhage

Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for 5% of all strokes, it puts a significant burden on many pa

动脉瘤性蛛网膜下腔出血（SAH）是一种危及生命的神经系统疾病：它是在膨出的血管（脑动脉瘤）破裂后在大脑中出血。尽管SAH占所有卒中的5%，但它给许多患者带来了沉重的负担。